141856-06-6

Basic information

• Product Name: 1,2-Ethanediamine, N-(phenylmethyl)-N'-(triphenylmethyl)-
• CAS NO: 141856-06-6
• Molecular Formula: C28H28N2
• Molecular Weight: 392.544
• Mol File: 141856-06-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1,2-Ethanediamine, N-(phenylmethyl)-N'-(triphenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Ethanediamine, N-(phenylmethyl)-N'-(triphenylmethyl)-(141856-06-6)
• EPA Substance Registry System: 1,2-Ethanediamine, N-(phenylmethyl)-N'-(triphenylmethyl)-(141856-06-6)

Safety Data

• Hazardous Substances Data: 141856-06-6(Hazardous Substances Data)

Upstream product

• 76-83-5 trityl chloride 
• 4152-09-4 N-benzylethylenediamine 

Downstream Products

• 141856-11-3 Methyl 4-amino>but-2-enoate 
• 146367-31-9 4-(4-benzyl-piperazin-2-yl)-butyric acid methyl ester 
• 146367-29-5 methyl 6-(benzyl(2-(tritylamino)ethyl)amino)-5-oxohexanoate 
• 141856-07-7 Methyl 5-amino>-4-oxopentanoate 
• 141856-05-5 2-Benzylhexahydropyrrolo<1,2-a>pyrazin-7(6H)-one 
• 134334-40-0 2-Benzylhexahydro-2H-pyrido<1,2-a>pyrazin-7(6H)-one 
• 1350457-55-4 1-(9-benzyl-7,7a,8,9,10,11-hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepin-5(6H)-yl)-2-(4-chlorophenyl)ethanone hydrochloride 
• 1350460-07-9 2-(4-benzyl-1-(2-nitrophenyl)piperazin-2-yl)acetic acid 
• 1350457-83-8 2-[2-(3-benzyl-2,3,4,4a,5,6-hexahydropyrazino[1,2-a][1,5]benzodiazepin-7(1H)-yl)-2-oxoethyl]pyridazin-3(2H)-one 
• 1350457-62-3 9-benzyl-5-[(2,2,3,3-tetramethylcyclopropyl)methyl]-5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine 
• 1350457-61-2 (9-benzyl-7,7a,8,9,10,11-hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepin-5(6H)-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 
• 1350457-57-6 9-benzyl-5-methyl-5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine 

Relevant articles and documents

Stereoselective synthesis of new conformationally restricted analogues of a potent CGRP receptor antagonist

(Chemical Equation Presented) A stereocontrolled racemic synthesis of conformationally restricted analogues 2a and 2b of a potent CGRP receptor antagonist 1 by novel functionalization of 2-substituted octahydropyrido[1,2-a] pyrazin-6-ones is described. Th

MACROCYLIC PYRIMIDINE DERIVATIVES

The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF

The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.